Abstract
Progressive deterioration of the incretin system has been shown to be a key component of the pathophysiology of type 2 diabetes. Improved understanding of the physiology underlying incretins has led to the development of new therapies that act through modulation of the incretin system. These agents offer some potential advantages over previous antidiabetes drugs and have been approved for use in type 2 diabetes. There are two broad classes of incretin-related therapies: dipeptidyl peptidase-4 inhibitors (sitagliptin and saxagliptin) and glucagon-like peptide-1 receptor agonists (exenatide and liraglutide). Although the two classes have some benefits in common—notably a low risk of hypoglycemia—they can be differentiated in terms of their pharmacology, efficacy and safety profiles, and clinical considerations. Introducing new therapies into everyday clinical use requires careful consideration of the practical implications of their use and how they fit in with current treatment regimens. With regard to incretin-related therapies, some patients with type 2 diabetes may benefit more from their use than others, whereas their use in a small subset of patients with type 2 diabetes should be avoided. With appropriate provider and patient education about the potential benefits and practicalities of incretin-related therapies, these agents should prove to be a valuable resource in type 2 diabetes management.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
